Skip to Main Content
Table 1—

Baseline characteristics and outcomes of individuals with symptomatic hypoglycemia who received subcutaneous glucagon versus oral glucose gel

Characteristic/outcomeSubcutaneous glucagonOral glucose gelComparison of glucagon versus glucose therapy
n 233 282  
Age (years) 55.7 ± 20.7 57.4 ± 20.2 P = 0.4 
Men 121 (51.9) 163 (57.8) P = 0.2 
Insulin use 189 (83.3) 202 (76.8) P = 0.1 
Initial CBGC [mmol/l (mg/dl)] 2.3 ± 0.8 [41 ± 14] 2.2 ± 0.7 [40 ± 13] P = 0.08 
Initial GCS 11 (8–13) 12 (10–14) P = 0.02 
Net increase in CBGC [mmol/l (mg/dl)] 1.4 ± 1.4 [25 ± 25] 0.5 ± 1.1 [9 ± 20] Mean difference: 0.9 (95% CI 0.6–1.1) [16 (95% CI 11–20)] 
Decline or no increase in GCS 34 (14.6) 149 (52.8) RR 0.3 (0.2–0.4) 
≥4 point increase in GCS 82 (35.2) 27 (9.6) RR 3.7 (2.5–5.5) 
Received more than one treatment dose 1 (0.4) 103 (36.7) RR 0.01 (0.002–0.08) 
Problems administering treatment 7 (3.0) 41 (14.5) RR 0.2 (0.09–0.4) 
Characteristic/outcomeSubcutaneous glucagonOral glucose gelComparison of glucagon versus glucose therapy
n 233 282  
Age (years) 55.7 ± 20.7 57.4 ± 20.2 P = 0.4 
Men 121 (51.9) 163 (57.8) P = 0.2 
Insulin use 189 (83.3) 202 (76.8) P = 0.1 
Initial CBGC [mmol/l (mg/dl)] 2.3 ± 0.8 [41 ± 14] 2.2 ± 0.7 [40 ± 13] P = 0.08 
Initial GCS 11 (8–13) 12 (10–14) P = 0.02 
Net increase in CBGC [mmol/l (mg/dl)] 1.4 ± 1.4 [25 ± 25] 0.5 ± 1.1 [9 ± 20] Mean difference: 0.9 (95% CI 0.6–1.1) [16 (95% CI 11–20)] 
Decline or no increase in GCS 34 (14.6) 149 (52.8) RR 0.3 (0.2–0.4) 
≥4 point increase in GCS 82 (35.2) 27 (9.6) RR 3.7 (2.5–5.5) 
Received more than one treatment dose 1 (0.4) 103 (36.7) RR 0.01 (0.002–0.08) 
Problems administering treatment 7 (3.0) 41 (14.5) RR 0.2 (0.09–0.4) 

Data are means ± SD, n (%), or median (25th–75th percentile). CBGC, capillary blood glucose concentration; RR, risk ratio.

Close Modal

or Create an Account

Close Modal
Close Modal